Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus DUOBRII.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus DUOBRII.
CAPEX vs DUOBRII
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Duobrii (halobetasol propionate and tazarotene) is a combination of a corticosteroid and a retinoid. Halobetasol propionate is a high-potency corticosteroid that acts via glucocorticoid receptors to induce anti-inflammatory, antiproliferative, and immunosuppressive effects. Tazarotene is a retinoid prodrug that is converted to its active form, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) to modulate gene expression, thereby reducing keratinocyte proliferation and promoting differentiation.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply a thin layer to affected areas of the scalp once daily for 8 weeks. For external use only.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Halobetasol propionate: 7.5 hours (terminal); Tazarotene: 9-12 hours (terminal).
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Halobetasol propionate: 60% renal, 40% fecal; Tazarotene: <1% renal, 93% fecal, 6% biliary.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid/Retinoid Combination